A very well written piece and a reminder of why many of us have been interested and invested in Starpharma for a loooong time. Thank you for your effort
@Gumnut70. Starpharma has so much potential but it is really time to start kicking goals with DEP. Until we progress into a Phase 3 trial, the DEP tech is essentially not validated IMO. Will it be this calendar year or next that’s the question...
Today SPL announced more free shares to certain employees as part of the Employee Performance Rights Plan. It’s possibly in relation to Viraleze reaching a ‘commercialisation’ milestone (which I don’t know for fact, just speculating) which as I mentioned many times last year is wholly positive for Jackie and other key execs but not necessarily shareholders.
Afterall, SPL raised massive amounts of money from a capital raising again last year, diluting us shareholders, to get another product to market, and regardless of whether Viraleze ever turns a profit or for that matter recoups the sunk costs of development, Jackie and others will get KPIs triggered and then financially rewarded.
Just still my glass half empty feeling and scepticism with all the Viraleze hoopla sorry. Not saying Viraleze can’t be a
commercial success, just needs elite marketing and luck.
